Teva Pharmaceutical Industries Net Change in Property, Plant, and Equipment 2010-2025 | TEVA
Teva Pharmaceutical Industries annual/quarterly net change in property, plant, and equipment history and growth rate from 2010 to 2025. Net change in property, plant, and equipment can be defined as the overall change in capital expenditures and sales of plant, property and equipment. This field is used if a company does not report separately sales and purchases of plant, property and equipment or is calculated as the sum of purchases and sales of PP&E
- Teva Pharmaceutical Industries net change in property, plant, and equipment for the quarter ending March 31, 2025 was $-0.127B, a 2.42% increase year-over-year.
- Teva Pharmaceutical Industries net change in property, plant, and equipment for the twelve months ending March 31, 2025 was $-1.132B, a 0.98% increase year-over-year.
- Teva Pharmaceutical Industries annual net change in property, plant, and equipment for 2024 was $-0.455B, a 0.66% decline from 2023.
- Teva Pharmaceutical Industries annual net change in property, plant, and equipment for 2023 was $-0.458B, a 4.58% decline from 2022.
- Teva Pharmaceutical Industries annual net change in property, plant, and equipment for 2022 was $-0.48B, a 91.24% increase from 2021.
Teva Pharmaceutical Industries Annual Net Change in Property, Plant, and Equipment
(Millions of US $) |
| 2024 |
$-455 |
| 2023 |
$-458 |
| 2022 |
$-480 |
| 2021 |
$-251 |
| 2020 |
$-511 |
| 2019 |
$-182 |
| 2018 |
$239 |
| 2017 |
$2,603 |
| 2016 |
$1,101 |
| 2015 |
$-248 |
| 2014 |
$-733 |
| 2013 |
$-844 |
| 2012 |
$-840 |
| 2011 |
$-774 |
| 2010 |
$-10 |
| 2009 |
$-448 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.207B |
$16.544B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
